The renoprotective potential of montelukast: a scoping review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Montelukast shows promise in protecting kidneys from damage by reducing inflammation and oxidative stress. This review highlights its potential benefits for acute kidney injury and other renal diseases.
Area Of Science
- Nephrology
- Pharmacology
- Immunology
Background
- Kidney damage arises from diverse factors, causing structural and functional impairment.
- Acute kidney injury (AKI) signifies a rapid decline in kidney function, whereas chronic kidney disease involves gradual deterioration over months.
- Renal injury mechanisms include impaired microcirculation, inflammation, and oxidative stress, with cysteinyl-leukotrienes (CysLTs) as key inflammatory mediators.
Purpose Of The Study
- To conduct a scoping review on the impact of montelukast on renal diseases.
- To evaluate the renoprotective effects of montelukast in experimental and human studies.
Main Methods
- Scoping review methodology utilizing PubMed, Scopus, and Web of Science databases.
- Inclusion of studies published up to 2022, with quality assessment and data extraction.
- Analysis of data based on predefined inclusion criteria for relevance and impact.
Main Results
- Thirty studies from eight countries were included, demonstrating montelukast's therapeutic effects.
- Montelukast showed efficacy in various experimental models of nephrotoxicity and AKI, including those induced by cisplatin, amikacin, and radiation.
- Positive outcomes were reported in human subjects with nephrotic syndrome, pyelonephritis, and other renal conditions, attributed to montelukast's anti-inflammatory, antioxidant, and anti-apoptotic properties.
Conclusions
- Montelukast exhibits significant potential as a renoprotective agent, especially in early-stage kidney injury.
- Its therapeutic benefits stem from mitigating inflammation, oxidative stress, and neutrophil infiltration.
- Further clinical research is warranted to fully elucidate montelukast's renoprotective mechanisms and applications.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
5-Lipoxygenase Inhibitors: Some drugs in this class, like zileuton (Zyflo), inhibit an enzyme called 5-lipoxygenase. This enzyme is crucial in synthesizing...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...